Celcuity (CELC) Cash from Investing Activities (2016 - 2025)
Celcuity (CELC) reported Cash from Investing Activities of $103.4 million for Q4 2025, up 175.32% on a YoY basis from $37.6 million in Q4 2024, and up 140.14% quarter-over-quarter from -$257.6 million in Q3 2025.
Celcuity (CELC) Cash from Investing Activities (2016 - 2025) Analysis & Trends
Celcuity has reported Cash from Investing Activities for 10 years, with the latest figure at $103.4 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 175.32% year-over-year to $103.4 million; the trailing twelve-month figure through Dec 2025 stood at -$64.1 million (down 1.61% YoY), and the FY2025 full-year result was -$64.1 million, down 1.61% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at $103.4 million, up from -$257.6 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $103.4 million in Q4 2025, with the low at -$257.6 million in Q3 2025.
- Historically, Cash from Investing Activities has averaged -$13.8 million across 5 years, with a median of -$10787.0 in 2021.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 1448587.69% — and 2023, when it jumped 188046.29%.
- Celcuity's Cash from Investing Activities stood at -$9939.0 in 2021, then sank by 1448587.69% to -$144.0 million in 2022, then surged by 71.37% to -$41.2 million in 2023, then jumped by 191.12% to $37.6 million in 2024, then jumped by 175.32% to $103.4 million in 2025.
- The last three Cash from Investing Activities figures came in at $103.4 million (Q4 2025), -$257.6 million (Q3 2025), and $65.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | 103.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 103.41 Mn |
| Dec 31, 2025 | 103.41 Mn |
| Sep 30, 2025 | -257.61 Mn |
| Sep 30, 2025 | -257.61 Mn |
| Jun 30, 2025 | 65.86 Mn |
| Jun 30, 2025 | 65.86 Mn |
| Mar 31, 2025 | 24.26 Mn |
| Mar 31, 2025 | 24.26 Mn |
| Dec 31, 2024 | 37.56 Mn |
| Dec 31, 2024 | 37.56 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | -106.07 Mn |
| Jun 30, 2024 | -106.07 Mn |
| Mar 31, 2024 | 3.54 Mn |
| Mar 31, 2024 | 3.54 Mn |
| Dec 31, 2023 | -41.22 Mn |
| Dec 31, 2023 | -41.22 Mn |
| Sep 30, 2023 | 6.25 Mn |
| Sep 30, 2023 | 6.25 Mn |